Bormioli Pharma returns to DCAT Week with a new, reinforced value proposition for the US market

Bormioli Pharma returns to DCAT Week in New York – from 21st to 24th March – introducing on the American market a truly renewed company.

Indeed, Bormioli Pharma never stopped investing, enhancing its commercial presence in the US with an on-site team and a warehouse to serve every industry need nationwide. Furthermore, it grew with new acquisitions in Europe to integrate its uniquely wide portfolio with tubing glass solutions dosage accessories for oral drugs, closures and pipettes.

The company has also increased efforts in innovation and sustainability, also reframing its product offer around specific segment needs: forTherapy, forHealth, forLife, addressing medical prescription, OTCs, nutraceuticals and food supplements segments.

More in detail, Bormioli Pharma will present a renewed forTherapy portfolio composed of Type I and tubing glass containers and vials, aluminum seals and rubber stoppers, together with scientific counsel provided to clients all along the process.

“Industry forecasts indicate that the parenteral drug segment will grow at a CAGR of +5.6% over the period 2020-2026 in the North American pharma market” commented Andrea Lodetti, CEO of Bormioli Pharma. “We are the only supplier that can provide the complete primary packaging solution and we have lead time capabilities that allow us to be agile and respond to the increasing saturation of the market. DCAT Week is an excellent opportunity to consolidate existing partnerships and generate new business opportunities”.

As far as forHealth portfolio is concerned, Bormioli Pharma will present new solutions for oral drops (e.g., CBD products, CNS applications, cosmetics), while the forLife portfolio will feature innovative dual-chamber solutions, allowing enhanced efficiency and safety with drug reconstitution. Thanks to an active layer, moisture presence can be minimized, further protecting APIs.

The company also promptly addresses sustainability concerns, with several product ranges and accessories manufactured in recycled plastics – mechanically and chemically recycled PET, and a cutting-edge manufacturing process able to capture CO2 – and in bio-based plastic solutions, together with endlessly recyclable glass solutions. All these solutions feature maximum quality, efficiency and aesthetics.

The CEO of Bormioli Pharma Andrea Lodetti and the company’s senior management will be available for any further enquiry during the event at Lotte New York Palace, Room 1726.